about
Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunityClinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population[Infections by Arcanobacterium haemolyticum: an emerging pathogen]Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patientsImmune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection.Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexesSoluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock.Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis CImpact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.Acute Q fever and the risk of developing endocarditis.[Ablation of the hyperconducting atrioventricular node in a patient with thyrotoxicosis induced by amiodarone]Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.Efficacy of directly observed treatment of HIV infection: experience in AIDS welfare homes.Dilutional hyponatremia in patients with cirrhosis and ascites.[Pancreatitis associated with Salmonella enteritidis bacteremia]Orofacial infections of odontogenic origin.Hepatocyte growth factor and chronic hepatitis C.Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients.Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis.HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.[Renal failure and insulin resistance: effect of the dialysis dose]Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.[Measurement of hepatitis C virus RNA 12 weeks after treatment predicts sustained virological response in HIV-HCV co-infected patients].[Neurocognitive impairment related to acquired immunodeficiency syndrome in socially-excluded former intravenous drug abusers].[Progressive multifocal leukoencephalopathy in the province of Cadiz, Spain]Assessment of the Palliative Prognostic Index in hospitalized oncologic patients treated by a palliative care team: impact of acute concomitant diseases.[Primary cutaneous nocardiosis caused by Nocardia farcinica].Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality.Pneumonia in HIV-infected patients in the HAART era: Incidence, risk, and impact of the pneumococcal vaccinationPeripheral Th17 cells expressing β7 intestinal homing receptor in recent and chronic HIV infectionsAproximación clínica y terapéutica a las infecciones de las vías respiratorias. Documento de Consenso de la Sociedad Andaluza de Enfermedades Infecciosas y de la Sociedad Andaluza de Medicina Familiar y ComunitariaUsefulness of Sputum Culture for Diagnosis of Bacterial Pneumonia in HIV-Infected PatientsExpression of proinflammatory cytokines and their inhibitors during the course of spontaneous bacterial peritonitisSerial analysis of serum and ascitic fluid levels of soluble adhesion molecules and chemokines in patients with spontaneous bacterial peritonitis[Primary intestinal lymphoma of the western type. Retrospective study of 24 patients]
P50
Q26773267-C3EEF2E1-AC0F-44D2-A8FA-4622D6424E0BQ28538921-24459D73-6ED8-4F4E-91A1-13356D0148B1Q30745346-154D595E-B7CD-4BCA-9AD0-97D63A1767BDQ33423922-E1A9961F-8CE2-4B36-8EAB-11DCFC1CC72BQ33889885-01964275-7C62-4F90-8367-1A056F63083EQ35182200-102F5D3D-BF20-40AF-87EF-7C1E085036AAQ35760270-108BCF96-F951-46AF-9902-3F78E7BD5DEEQ36336058-8C6116C4-64FB-4869-9A8C-C5A069639D33Q36553967-F4766412-743A-4AC6-B5CA-2B46684FB361Q37642114-DB7A1F6E-4502-49C5-A02E-B0540A18B696Q40166636-C7E8C754-A10E-413A-BDD0-1408DC2946DFQ42566259-35FEDEDF-22AC-4F09-A054-6CC3634064B2Q42979333-8B030642-1AFF-47CA-A5F5-6F52DB971CF0Q42981205-CA07CBD3-C2CB-4C73-8746-557CDFAAF531Q43039689-A7BCEA51-13E3-4146-8464-F9572AD1E109Q43041379-EBEBE8FD-C573-4E2B-8516-0387FDEFECB9Q43757922-5F0DA6E7-0573-44D3-B9E5-2CAF34DE2E6AQ43873691-8F5976BA-70ED-4B2D-B995-EEF806E0A1E4Q44844332-86E4ACCC-8C5C-449D-9468-A130F83FC873Q45006417-500ABBFC-E0FD-4557-B395-043844D789F8Q45325984-EA6F545C-37C5-481E-A9F1-F1DC73DD6637Q45358296-A3CCE964-3900-4D54-B4AD-0E28862283B5Q45381381-375A0265-9E1B-4ED6-BC6F-89102F4384B2Q45408484-DC2BF7A7-5F9F-4647-9FD7-15A9ECA77074Q45489050-2C7EDFBD-5B8B-4FCC-A89F-3C86AF009A8CQ46967528-3A55B1F6-E6D1-41B2-AFDC-5C8C59BF760DQ50546267-39911713-F2CE-4AEE-A8E6-E9A2C736668DQ50555185-F7B285CB-E48E-49C7-AAFC-E6249124DB67Q51890767-D57E422E-D137-4331-8EE6-CCBF04648D91Q53395239-5F309A27-DC09-410D-B280-3A347B0A99A6Q54222399-8E19B29A-6DFC-40E7-A638-A60ADE857722Q54337699-1F86C1B8-B9E5-4040-A88E-2BE12E0C6067Q55378575-272F45E5-FDE2-456B-AD3D-713A31EE2F6BQ58322068-5E6DF4FA-0A54-4DA4-A056-22FACAFC724AQ59354682-994FBA91-336E-4724-A583-DD4514CD93E2Q61813006-BE626DDA-F725-4340-9B2E-BEE93B2E508CQ61813026-58062B25-59A9-48AA-A236-E5EC1859FE1EQ63433701-9088FE88-2E22-42AA-B220-F686A1C52128Q63433702-CEECA2DF-7852-4C28-BE9B-DA46E6147F20Q68296468-151717C9-BC58-4D16-8F6C-BDB02E4214B6
P50
description
researcher ORCID ID = 0000-0002-7482-5828
@en
wetenschapper
@nl
name
José-Antonio Girón-González
@ast
José-Antonio Girón-González
@en
José-Antonio Girón-González
@nl
type
label
José-Antonio Girón-González
@ast
José-Antonio Girón-González
@en
José-Antonio Girón-González
@nl
prefLabel
José-Antonio Girón-González
@ast
José-Antonio Girón-González
@en
José-Antonio Girón-González
@nl
P108
P106
P21
P31
P496
0000-0002-7482-5828